NCT00802906

Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Johann Wolfgang Goethe University Hospital · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

Detailed description

To evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score, OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control group without treatment over 10 months.

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DEVICE	subthreshold micropulselaser	on demand if leakage is persistent or recurs after initial treatment
DRUG	bevacizumab	1.5 mg initial intravitreal injection

Timeline

• Start date: 2007-05-01
• Primary completion: 2010-11-01
• Completion: 2010-12-01
• First posted: 2008-12-05
• Last updated: 2012-09-27

Locations

1 site across 1 country: Germany